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Poster Session-I 91duration of hospital stay (Table). In summary, within the first 100
days after HCT, transplantation with MA MRD, NMA MRD and
NMA UCB has similar costs while MA UCB HCT is more costly.
These higher costs can be attributed to lengthier hospital stay due
to slower engraftment and a higher incidence of graft failure. Strat-
egies to enhance engraftment (e.g. better HLA matched units, in-
creasing cell dose using two units) will decrease the costs of UCB
transplantation. Long-term costs of UCB HCT may be lower due
to the lower incidence of chronic GVHD, but this warrants further
investigation.
Multivariate analysis for costs within the first 100 days follow-
ing HCT
Variable Ratio (95% CI) P-valueTransplant type
MA MRD 1.0
MA UCB 1.3 (1.1-1.5) 0.05
NMA MRD 1.0 (0.9-1.2) 0.82
NMA UCB 1.0 (0.8-1.2) 0.96Graft failure
No 1.0
Yes 1.8 (1.7-1.9) \0.001Dialysis
No 1.0
Yes 1.3 (1.1-1.5) 0.05Mechanical ventilation
No 1.0
Yes 1.3 (1.2-1.4) 0.004Hospital stay, tertiles
\32 days 1.0
32-48 days 1.0 (0.8-1.2) 0.98
.48 days 2.1 (1.9-2.3) \0.001Other variables considered in themodel included age at HCT, Karnofsky
performance score at HCT, disease risk, previous transplant, CMV sta-
tus, acute GVHD, hepatic veno-occlusive disease, and total (inpatient
and outpatient) medical encounters (HLA match correlated with trans-
plant type and was not included)250
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PTLD resulting from EBV reactivation after stem cell transplan-
tation is a potentially fatal complication observed with T-cell de-
pleted, matched unrelated donor (MUD), and umbilical cord
blood (UCB) transplants, and the use of ATG-associated condition-
ing. Real-time quantitative (quant) PCR for EBV DNA is a highly
sensitive and specific test for EBV reactivation. Since 5/2006, we
screen allogeneic transplant recipients using quant PCR for EBV
DNA weekly until day 100 and monthly thereafter. If EBV DNA ti-
ter is.1000 copies, we initiate rituximab 375mg/m2 IVweekly for 4
weeks. Of 53 allogeneic transplants performed between 5/2006 and
8/2008, 14 patients (pts) (26%) (11 male, 3 female) had EBV reacti-
vation. Median age was 50.5 (range 20–71) yrs. All pts with EBV re-
activation had high-risk malignancies (secondary AML, AML,
CML, CLL, aplastic anemia, Hodgkin’s lymphoma, myelofibrosis).
Graft sources were UCB (N5 8), matched-related donor (MRD) (N
5 4), and MUD (N 5 2). Myeloablative conditioning was used in 3
pts; 11 patients (UCB, N 5 7) received reduced-intensity (RIC) or
nonmyeloablative (NST) regimens. ATGwas included in the condi-
tioning regimen in all pts except for 2 MUD pts and 2 MRD pts. All
pts received cyclosporine or FK 506 based GVHD prophylaxis. Me-
dian follow up is 289 (range 76–489) days. Relapse occurred in 3 pts
with an overall survival of 79%. One pt died of treatment-related
mortality; 2 pts died of disease relapse. Grade 2–4 acute GVHDwas seen in 7; 2/11 pts had extensive chronic GVHD. Median time
to diagnosis of EBVpositivitywasT160.5 (range 21–302)with ame-
dian EBV titer of 1720 (range 656–5700). Twelve pts received ritux-
imab. One pt had treatment initiated with an EBV titer\1000. This
pt had a positive qualitative EBVPCR test one week prior to the pos-
itive quant EBV PCR (656). All but one pt became EBV negative by
the end of the course of rituximab. This pt went on to receive 6
weekly treatments of rituximab and was started on valganciclovir.
One pt did not receive rituximab for an EBV titer of 886; 6 weeks
later had an EBV titer .1,000,000 and died of multi-organ failure.
Majority of pts received RIC orNST regimens or anUCB transplant
regimen using ATG. Given the morbidity and mortality of PTLD,
weekly testing for EBV DNA by quant PCR with preemptive treat-
ment with rituximab for pts with EBV titers.1000 may be effective
in preventing EBV associated PTLD.251
CHG WATERLESS BATH SYSTEM SIGNIFICANTLY REDUCED BSI IN PEDI-
ATRIC BMT PATIENTS
Rosselet, R.M., Termuhlen, A.M., Skeens, M., Garee, A., Laudick, M.,
Ryan-Wenger, N. Nationwide Children’s Hospital, Columbus, OH
Objectives: The primary objective is to determine whether pedi-
atric blood and marrow transplant (BMT) patients bathed daily with
chlorhexidine gluconate (CHG) waterless bath system have lower in-
cidence of Staphylococcus epidermis blood stream infections and total
blood stream infections (BSI) compared to patients bathed with
the standard CHG soap and water method. Secondary objectives
are to determine the time efficiency and cost effectiveness of water-
less bath system versus the standard soap and tap water bath.
Background: With continuous improvements in BMT technol-
ogy and increasing survival, infection remains a leading cause ofmor-
bidity and mortality among transplant patients.
Methods: A non-equivalent two-group quasi-experimental study
was conducted using historical controls (N5 25) who received soap
and water bathing during their admission for BMT versus patients
bathed with CHG waterless bath system (N 5 25). A time and mo-
tion analysis (N 5 20) during the bathing procedure was conducted
by an independent observer, who recorded number of minutes spent
on the entire bathing procedure and the amount and type of mate-
rials/supplies used for each type bath. Data regarding infections
were collected by chart review. Outcomes measured included inci-
dence of total BSI and Staphylococcus epidermis BSI. Secondary out-
comes included the time and cost of the two bathing systems.
Results: Independent t-tests were used to compare groups. Pedi-
atric BMT patients bathed with CHG waterless bath intervention
had significantly fewer BSI overall (x vs. y) and Staphylococcus epidermis
BSI (x vs. y) (p5 0.017, 0.009 respectively). The cost of materials per
bath was nearly identical, ($14.40 per soap and tap water bath versus
$14.23 per CHGwaterless bath). However, staff direct care time was
nearly three times longer for tap water bath (18.3 minutes per bath)
than the waterless bath (6.6 minutes per bath). The time difference
was statistically significant (t 5 4.537, p\ 0.001), which translates
to lower cost for the waterless bath method.
Conclusions:Daily bathing of patients with CHG waterless bath
system significantly decreased BSI, especially with Staphylococcus
epidermis. It is an easy, time-efficient, cost-effective intervention to
decrease these infections in pediatric patients undergoing a BMT.252
COMPARISION AND COST EFFECTIVENESS OF BRONCHOSCOPIC AND
NON-BRONCHOSCOPIC BRONCHOALVEOLAR LAVAGE IN HEMATOLOGI-
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Introduction: Pulmonary infiltrates are common in critically ill
patients with hematological malignancies and also in post stem cell
transplant (SCT) recipients. Radiological changes of parenchymal
infiltrates are non-specific and can be caused by infection, inflamma-
tion, fluid, and parenchymal bleeding. Bronchoalveolar lavage (BAL)
is commonly performed for microbiological sampling.
